Alnylam Pharmaceuticals, Inc. or Bio-Techne Corporation: Who Manages SG&A Costs Better?

Biotech Giants' SG&A Strategies: Alnylam vs. Bio-Techne

__timestampAlnylam Pharmaceuticals, Inc.Bio-Techne Corporation
Wednesday, January 1, 20144452600060716000
Thursday, January 1, 201560610000119401000
Friday, January 1, 201689354000140879000
Sunday, January 1, 2017199365000199243000
Monday, January 1, 2018382359000240636000
Tuesday, January 1, 2019479005000264359000
Wednesday, January 1, 2020588420000260583000
Friday, January 1, 2021620639000324951000
Saturday, January 1, 2022770658000372766000
Sunday, January 1, 2023795646000378378000
Monday, January 1, 2024975526000396826000
Loading chart...

Unlocking the unknown

Alnylam Pharmaceuticals vs. Bio-Techne: A Decade of SG&A Management

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and profitability. Over the past decade, Alnylam Pharmaceuticals and Bio-Techne Corporation have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Alnylam's SG&A expenses surged by over 1,600%, reflecting its aggressive expansion strategy. In contrast, Bio-Techne's expenses grew by approximately 520%, indicating a more measured approach.

While Alnylam's expenses peaked in 2023, Bio-Techne continued its steady climb, with 2024 projections showing a further increase. This divergence highlights the strategic choices each company makes in balancing growth with cost efficiency. As investors and industry watchers analyze these trends, the question remains: which strategy will yield better long-term returns?

Explore the data to uncover how these biotech giants navigate the complexities of SG&A management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025